Table 1.

Characteristics of the included studies.

Author/Country	Risk Factor	Nystatin Group			Control Group			Nystatin Group				Control Group
		Age (Mean)	Sex	N	Age (Mean)	Sex	N	Formulation	Dose	Frequency (Times/day)	Duration (Days)	Medication	Formulation	Dose	Frequency	Duration (Days)
Afroozi et al. 2019 [28], Iran	Denture	67.4 y	-	33	67.6 y	-	33	Sol	100,000 IU	3 times a day	15	PDT	-	-	2 sessions	15
Alrabiah et al. 2019 [29], Saudi Arabia	Denture	-	-	18	-	-	18	Susp	100,000 IU	4 times a day	14	PDT	-	-	twice in one week	30
Alves et al. 2020 [30], Brazil	Denture	69 y	-	35	70 y	F = 19 M = 11	30	Susp	100,000 IU/mL)	4 times a day	15	PDT	-	-	6 sessions	15
Araújo et al. 2021 [35], Brazil	Denture	57 y	-	18	-	-	18	Sol	1,000,000 IU	3 times a day	15	CZ	oral spray	-	3 times a day	15
Bakhshi et al. 2012 [31], Iran	Denture	73.52 y	-	20	-	-	20	Sol	100,000 IU/ml	3 times a day	30	GE	Sol	40 mg/ml	3 times a day	30
Gonoudi et al. 2021 [32], Iran	Denture	60.93 y	-	14	55.86 y	-	14	Susp	100,000 IU	4 times a day	14	ZM	Sol	5 ml	5 times a day	14
Johnson et al. 1989 [39], USA	Denture	-	-	8	-	-	8	Pas	200,000 IU	5	14	Placebo	Pastilles		5	14
		-	-	8	-	-	8	Pas	400,000 IU	5	14	Placebo	Pas		5	14
Labban et al. 2021 [33], Saudi Arabia	Denture	56.9 y	-	15	57.2 y	-	15	Susp	100,000 IU/mL	4 times a day	15	PDT	-	-	6 sessions	15
Li et al. 2014 [34], China	Denture	64.84 y	F = 24 M = 7	31	62.72 y	F = 29 M = 5	34	Paste	2%	3	30	NYT + Pb	Paste + Lozenges		3	30
Mima et al. 2012 [40], Brazil	Denture	62.45 y	-	20	61.25 y	-	20	Susp	100 000 IU	4 times a day	15	PDT	-	-	6 sessions	15
Nairn et al. 1975 [37], England	Denture	-	-	13	-	-	18	Pas	500,000 IU	4	30	AMB	Lozenges	10 mg	4	30
		-	-	13	-	-	15	Pas	500,000 IU	4	30	Placebo
Pinelli et al. 2013 [38], Brazil	Denture	81.4 y	-	10	-	-	10	Sol	100,000 IU	4 times a day	30	RC	Sol	-	-	30
		81.4 y	-	10	-	-	10	Sol	100,000 IU	4 times a day	30	MIC	Gel		4 times a day	30
Silva et al. 2012 [36], Brazil	Denture	62.5 y	-	20	59.5 y	-	20	Susp	100,000 IU/ml	4	14	DM	Irr		Once per week	14
		62.5 y	-	20	56.8 y	-	20	Susp	100,000 IU/ml	4	14	DM	Irr		3 times per week	14
Sanita et al. 2012 [42], Brazil	Denture in diabetic patients	62.6 y	-	10	62.2 y	-	10	Susp	100,000 IU/m	4	14	DM	Irr		3 times per week	14
Thompson et al. 1986 [41], England	Respiratory disease	59 y	-	18	-	-	18	Pas	100,000 IU	4	7	NYT	Susp	100 000 units	4	7
Goins et al. 2002 [44], USA	Infants	1–12 mon	-	28	1–12 mon	-	17	Susp	100,000 IU	4	10	FLC	Susp		1 per day	7
Hoppe 1997 [46], Multicenter study	Infants	130 days	F = 0 M = 77	85	132 days	F = 0 M = 95	98	Susp	100,000 IU	4	12	MIC	Gel		4	12
Hoppe et al. 1996 [45], Multicenter study	Infants	5 months	-	35	5 mon	-	27	Gel	250,000 IU	4	14	MIC	Gel		4	14
		5 months	-	35	5 mon	-	27	Gel	100,000 IU	4	14	MIC	Gel		4	14
Flynn et al. 1995 [43], USA	Infants Children	6 months–13 y	-	88	6 mon–13 y	-	94	Susp	400,000 IU	4	14	FLC	Susp			14
Meunier et al. 1990 [51], Belgium	Cancer patients	-	F = 10 M = 14	24	-	F = 8 M = 10	18	Susp + Pas	1000,000 IU + 100,000 IU	3	10 to 12	KCZ	Tab			10 to 12
Mukherjee et al. 2017 [47], Multicenter study	HIV	-	F = 66 M = 45	111	-	F = 62 M = 48	110	Susp	500,000 IU	4	14	GV	Sol			14
Pons et al. 1997 [49], USA	HIV, AIDS	38 y	-	84	38 y	-	83	Susp	500,000 IU	4	14	FLC	Susp			14
Nyst et al. 1992 [48], Zaire	AIDS	35.4 y	-	47	34.5 y	-	49	Susp	200,000 IU	4	14	GV	Susp			14
		35.4 y	-	47	34.5 y	-	45	Susp	200,000 IU	4	14	KCZ	Troche			14
Blomgren et al. 1998 [50], Sweden	Multigroup patients	60.7 y	-	33	58.4 y	-	34	Sol	100,000 IU	4	21	FLC	Cap			7

HIV = human immunodeficiency virus; AIDS = acquired immunodeficiency syndrome; PDT—Photodynamic therapy; CZ—Cinnamomum zeylanicum; GE—Garlic extract; ZM—Zataria multiflora; NYT—nystatin; Pb—probiotics; AMB—Amphotericin B; RC—Ricinus communis; MIC—Miconazole; DM—Denture microwave; FLC—Fluconazole; KCZ—Ketoconazole; GV—Gentain violet; Susp—Suspension; Sol—Solution; Tab—Tablet; Cap—Capsule; Irr—Irradiation; Pas—Pastilles.